ArticleReviews in cardiovascular medicine2026
Correlation Between the Atherogenic Index of Plasma and Major Adverse Long-Term Prognosis in Patients With Coronary Artery Disease and Stage 2-5 Chronic Kidney Disease.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic utility of the atherogenic index of plasma (AIP) in patients with coronary artery disease (CAD) and chronic kidney disease (CKD) remains unclear. Therefore, this study aimed to evaluate the association between AIP and long-term outcomes in patients with CAD and stage 2-5 CKD. Methods: This retrospective study included 1816 patients with angiographically confirmed CAD and stage 2-5 CKD treated at a tertiary center between January 2019 and June 2023. The AIP was calculated as log10 (TG/HDL-C). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), including cardiac death, non-fatal myocardial infarction (MI), non-fatal stroke, and ischemia-driven revascularization. Patients were stratified into high- and low-AIP groups according to the optimal receiver operating characteristic (ROC) curve-derived cutoff value (0.148). The association between the AIP and incidence of MACCEs was primarily evaluated in the overall cohort using multivariable Cox regression. To minimize the influence of confounding and improve comparability between groups, Kaplan-Meier analysis and model performance metrics, including the C-statistic, net reclassification improvement (NRI), and integrated discrimination improvement (IDI), were also assessed. Results: MACCEs occurred in 379 patients (20.9%). High AIP independently predicted increased risk of MACCEs (adjusted hazard ratio (HR): 1.95; 95% confidence interval (CI): 1.45-2.63; Conclusions: AIP is an independent predictor of adverse long-term outcomes in patients with CAD and stage 2-5 CKD. Integration of the AIP into existing risk models significantly enhances risk stratification and facilitates the identification of high-risk individuals for personalized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.